The Breast Cancer, Early Disease: Toxicity from Therapy with Epirubicin Regimens – Cardiac Assessment and Risk Evaluation (BETTER-CARE) Study : design, set-up and analysis of a prospective multicentre collaboration to investigate the pharmacogenetics of anthracycline cardiotoxicity, using cardiovascular magnetic resonance imaging
Anthracyclines are highly effective chemotherapy drugs. However, their use is associated with anthracycline cardiotoxicity (AC), which may result in premature heart failure. Risk of AC is related to cumulative dose, but is also highly idiosyncratic. Effective tests to predict susceptibility are lack...
Main Author: | Kotwinski, P. J. |
---|---|
Published: |
University College London (University of London)
2013
|
Subjects: | |
Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.626031 |
Similar Items
-
Cardiovascular magnetic resonance imaging in early anthracycline cardiotoxicity
by: Hugh Montgomery, et al.
Published: (2009-01-01) -
The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity
by: Kotwinski Paul, et al.
Published: (2013-01-01) -
Anthracycline Cardiotoxicity
by: Umberto Campia, MD, MSc, et al.
Published: (2020-06-01) -
Cardiotoxicity of Anthracyclines
by: Daniela Cardinale, et al.
Published: (2020-03-01) -
Detection of anthracycline induced cardiotoxicity by cardiac biomarkers
Published: (2020-11-01)